Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$17.59 -0.6%	$19.29	$10.21 ▼ $25.67	$4.20B	0.43	3.66 million shs	3.04 million shs
CTMX CytomX Therapeutics	$2.38 -0.4%	$2.32	$0.40 ▼ $3.10	$191.88M	2.05	2.21 million shs	973,923 shs
PBYI Puma Biotechnology	$3.36 -2.3%	$3.40	$2.23 ▼ $4.13	$166.76M	1.29	412,601 shs	303,932 shs
TRDA Entrada Therapeutics	$6.38	$7.51	$6.26 ▼ $21.79	$242.14M	-0.11	134,526 shs	89,749 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	-1.61%	-3.54%	-13.28%	-16.99%	+28.84%
CTMX CytomX Therapeutics	-0.42%	-4.02%	-2.85%	+264.33%	+58.28%
PBYI Puma Biotechnology	-0.58%	-4.44%	-0.29%	+20.28%	-12.91%
TRDA Entrada Therapeutics	+0.16%	-15.72%	-13.90%	-21.53%	-64.08%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMA ADMA Biologics	3.8679 of 5 stars	3.7	1.0	0.0	2.8	2.5	3.1
CTMX CytomX Therapeutics	4.1735 of 5 stars	3.5	1.0	4.7	2.4	1.7	1.3
PBYI Puma Biotechnology	4.2353 of 5 stars	3.5	2.0	0.0	2.6	4.2	3.1
TRDA Entrada Therapeutics	3.3261 of 5 stars	3.6	1.0	0.0	3.0	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	3.33	Buy	$27.67	57.29% Upside
CTMX CytomX Therapeutics	3.00	Buy	$5.33	124.09% Upside
PBYI Puma Biotechnology	3.00	Buy	$7.00	108.33% Upside
TRDA Entrada Therapeutics	3.25	Buy	$25.67	302.30% Upside

Current Analyst Ratings Breakdown

Latest PBYI, ADMA, CTMX, and TRDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/20/2025	TRDA Entrada Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/15/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$2.50 ➝ $5.00
5/15/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $5.00
5/12/2025	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00 ➝ $6.00
5/8/2025	ADMA ADMA Biologics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$25.00 ➝ $32.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$426.45M	9.85	$0.53 per share	33.22	$1.48 per share	11.89
CTMX CytomX Therapeutics	$138.10M	1.39	$0.36 per share	6.63	($0.01) per share	-238.00
PBYI Puma Biotechnology	$230.50M	0.72	$0.83 per share	4.06	$1.88 per share	1.79
TRDA Entrada Therapeutics	$172.22M	1.41	$1.59 per share	4.01	$11.46 per share	0.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	$197.67M	$0.85	20.69	25.49	N/A	45.01%	47.16%	30.51%	8/6/2025 (Estimated)
CTMX CytomX Therapeutics	$31.87M	$0.48	4.96	N/A	N/A	28.22%	-553.71%	32.21%	8/14/2025 (Estimated)
PBYI Puma Biotechnology	$30.28M	$0.77	4.36	8.84	N/A	16.37%	49.35%	18.25%	7/30/2025 (Estimated)
TRDA Entrada Therapeutics	$65.63M	$0.81	7.88	N/A	N/A	14.39%	5.84%	4.61%	8/12/2025 (Estimated)

Latest PBYI, ADMA, CTMX, and TRDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ADMA ADMA Biologics	$0.14	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	CTMX CytomX Therapeutics	-$0.05	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	TRDA Entrada Therapeutics	-$0.86	N/A	N/A	N/A	$8.17 million	N/A
8/7/2025	Q2 2025	PBYI Puma Biotechnology	$0.11	N/A	N/A	N/A	$52.00 million	N/A
5/12/2025	Q1 2025	CTMX CytomX Therapeutics	$0.18	$0.27	+$0.09	$0.27	$35.42 million	$50.92 million
5/8/2025	Q1 2025	TRDA Entrada Therapeutics	-$0.78	-$0.42	+$0.36	-$0.42	$10.98 million	$8.75 million
5/7/2025	Q1 2025	ADMA ADMA Biologics	$0.16	$0.14	-$0.02	$0.11	$116.40 million	$114.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
PBYI Puma Biotechnology	N/A	N/A	N/A	N/A	N/A
TRDA Entrada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.22	6.58	3.36
CTMX CytomX Therapeutics	N/A	1.73	1.73
PBYI Puma Biotechnology	0.11	1.53	1.43
TRDA Entrada Therapeutics	N/A	21.88	21.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
CTMX CytomX Therapeutics	67.77%
PBYI Puma Biotechnology	61.29%
TRDA Entrada Therapeutics	86.39%

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.50%
CTMX CytomX Therapeutics	6.60%
PBYI Puma Biotechnology	23.30%
TRDA Entrada Therapeutics	8.11%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	530	238.73 million	230.38 million	Optionable
CTMX CytomX Therapeutics	170	80.62 million	75.30 million	Optionable
PBYI Puma Biotechnology	200	49.63 million	38.07 million	Optionable
TRDA Entrada Therapeutics	110	37.95 million	34.88 million	Optionable

PBYI, ADMA, CTMX, and TRDA Headlines

Recent News About These Companies

5am Ventures v sells Entrada Therapeutics (TRDA) stock for $202k

July 13, 2025 | investing.com

Entrada therapeutics (TRDA) director Parmar sells $202k in stock

July 13, 2025 | investing.com

Ventures V. L.P. 5Am Sells 6,935 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

July 12, 2025 | insidertrades.com

Insider Selling: Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Sells 6,935 Shares of Stock

July 11, 2025 | marketbeat.com

Ventures V. L.P. 5Am Sells 20,065 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

July 11, 2025 | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Sells $202,500.00 in Stock

July 11, 2025 | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Shares Down 3.6% - Should You Sell?

July 8, 2025 | marketbeat.com

Entrada Therapeutics (TRDA) 10% owners sell $866k in stock

July 3, 2025 | investing.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Ventures V. L.P. 5Am Sells 6,422 Shares

July 2, 2025 | insidertrades.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Kush Parmar Sells 75,000 Shares

July 1, 2025 | marketbeat.com

Insider Selling: Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Sells 6,422 Shares of Stock

July 1, 2025 | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Ventures V. L.P. 5Am Sells 18,578 Shares

July 1, 2025 | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Ventures V. L.P. 5Am Sells 19,265 Shares

July 1, 2025 | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Kush Parmar Sells 25,000 Shares

July 1, 2025 | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Ventures V. L.P. 5Am Sells 55,735 Shares

July 1, 2025 | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Upgraded to "Hold" at Wall Street Zen

June 27, 2025 | marketbeat.com

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

June 3, 2025 | globenewswire.com

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 2, 2025 | globenewswire.com

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients ...

May 29, 2025 | morningstar.comM

Entrada Therapeutics to start DMD trial in Q3 2025

May 29, 2025 | investing.com

Entrada Therapeutics Receives EU Authorization to Proceed with ELEVATE-45-201 Clinical Study for Duchenne Muscular Dystrophy, Set to Begin in Q3 2025

May 29, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBYI, ADMA, CTMX, and TRDA Company Descriptions

ADMA Biologics NASDAQ:ADMA

$17.59 -0.10 (-0.57%)

Closing price 04:00 PM Eastern

Extended Trading

$17.60 +0.01 (+0.06%)

As of 07:57 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

CytomX Therapeutics NASDAQ:CTMX

$2.38 -0.01 (-0.42%)

Closing price 04:00 PM Eastern

Extended Trading

$2.39 +0.01 (+0.42%)

As of 07:52 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Puma Biotechnology NASDAQ:PBYI

$3.36 -0.08 (-2.33%)

Closing price 04:00 PM Eastern

Extended Trading

$3.39 +0.03 (+0.77%)

As of 06:25 PM Eastern

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Entrada Therapeutics NASDAQ:TRDA

$6.38 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$6.46 +0.08 (+1.25%)

As of 07:25 PM Eastern

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time